WARREN, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, filed a Registration Statement on Form S-1 on June 21, 2024, to register the issuance of previously disclosed shares of the Company’s common stock as well as the resale of shares of common stock and warrants by existing securityholders. This new registration statement does not relate to any previously undisclosed new issuances of dilutive securities.

View original post here:
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive...